Claude is the responsible for the development of the strategy and the clinical phases related to the Malaria pillar of the Global Health Institute.  Additionally, he is supporting the external financing approaches for the Institute.

Before joining Merck KGaA, Darmstadt, Germany, Claude worked with MMV (Medicines for Malaria Venture) where he was responsible for the portfolio management and the fundraising strategy. Claude has a strong background and expertise in malaria drug and vaccine development. At MMV, he also co-led the development of Pyramax® up to the successful submission of the dossier to EMA in 2010. He contributed to strengthen capacities in the participating clinical centers.

Prior to MMV, he developed the first seamless Phase IIb/III clinical study in malaria for Coartem D at Novartis and was involved in anti-viral drug development. In addition, Claude has several years of experience in vaccines research and immunology. He is co-inventor of a malaria vaccine, MSP3, and he holds a PhD in biology obtained at the Pasteur Institute and a master in management of innovation.